A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.

Cihan YurdaydinOnur KeskinEsra YurdcuAysun ÇalişkanSoner ÖnemFatih KarakayaÇağdaş KalkanErsin KaratayliSenem KaratayliIngrid ChoongDavid ApelianChristopher KohTheo HellerRamazan IdilmanMithat A BozdayiJeffrey S Glenn

Published in: Hepatology (Baltimore, Md.) (2021)

Lonafarnib, boosted with low dose ritonavir, is a promising all-oral therapy, and maximal efficacy achieved with PEG-IFNα addition. The identified optimal regimens support the first Phase 3 (D-LIVR) study of lonafarnib for the treatment of HDV.

Keyphrases

low dose
phase ii
clinical trial
dendritic cells
randomized controlled trial
immune response
high dose
open label
stem cells
drug delivery
mesenchymal stem cells
antiretroviral therapy
bone marrow
resistance training
double blind
study protocol
cell therapy
high intensity